Tasly Pharmaceutical’s Nine-Month Financials Show Increased Profit
Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials indicate positive cash flow and a stable asset base, reflecting a solid financial position. This could influence China Resources Pharmaceutical Group’s market standing and investor confidence, as the group holds a 28% equity interest in Tasly. Current market cap for China Resources is HK$30.6B with a technical sentiment signal to sell.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an announcement.
Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials reveal a positive cash flow change and a stable asset base, suggesting a solid financial position for Tasly, which could impact China Resources Pharmaceutical Group’s overall market standing and investor confidence.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a prominent player in the pharmaceutical industry, focusing on manufacturing and distributing a wide range of pharmaceutical products. The company holds a significant market position, with a 28% equity interest in Tasly Pharmaceutical, a subsidiary listed on the Shanghai Stock Exchange.
Average Trading Volume: 16,744,630
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.6B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.
